Navigation Links
Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival
Date:10/25/2011

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced results from a Bayer HealthCare Pharmaceuticals Phase 3 trial evaluating the investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies. The trial met its primary endpoint of statistically significant improvement in overall survival. This is the result of a pre-planned interim analysis conducted by an independent Data Monitoring Committee (DMC) of the CORRECT (Patients with metastatic colorectal cancer treated with regorafenib or placebo after failure of standard therapy) trial. Per the recommendation of the DMC, the study has been unblinded and patients in the placebo arm will be offered treatment with regorafenib. In this trial, the safety and tolerability of regorafenib were generally as expected.  Data from the study are expected to be presented at a forthcoming scientific meeting.

Onyx recently entered into an agreement with Bayer under which Bayer will pay Onyx a royalty on any future global net sales of regorafenib in oncology.

"Patients with metastatic colorectal cancer are in need of new treatment options, and these data demonstrate that regorafenib increased overall survival," said Ted W. Love, M.D., Executive Vice President, Research and Development and Technical Operations at Onyx Pharmaceuticals. "We look forward to seeing this promising therapy become available to patients as quickly as possible."

Bayer will continue discussions with health authorities worldwide, including the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA), regarding next steps in filing for approval of regorafenib in the treatment of mCRC.

About the CO
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. S*BIO to Initiate Global Phase 3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of Myelofibrosis (MF)
2. Mesoblast Cleared to Begin First Phase 2 Clinical Trial for Eye Diseases
3. Data From Phase 2 Clinical Studies of Telotristat Etiprate in Patients With Carcinoid Syndrome to be Presented at North American Neuroendocrine Tumor Society Meeting
4. DIFICID™ Demonstrated Early Superiority in the First 12 Days Compared to Vancomycin in New Analysis of Phase 3 Study Results
5. First Results From Ongoing Phase III Trial Show Malaria Vaccine Candidate, RTS,S* Reduces the Risk of Malaria by Half in African Children Aged 5 to 17 Months
6. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
7. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
8. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
9. Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology
10. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
11. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Kan. , Dec. 18, 2014   ... ), a biopharmaceutical company focused on the licensing, ... animals, today announced positive results from its pivotal ... drug for treating pain in dogs with osteoarthritis. ... in pain assessment scores that were statistically significant ...
(Date:12/17/2014)... -- Los beneficios y ganancias están por ... gasto en investigación y desarrollo   En ... septiembre de 2014) ZEISS aumentó sus ingresos en un ... anterior: 4.190 millones de euros) a pesar de los ... un 14 por ciento, a 360 millones de euros. ...
(Date:12/17/2014)... 2014 With advancements in neurological and ... is seeing new growth, according to Kalorama Information. ... for the majority of market volume, newer 3T ... which are creating opportunities for more sophisticated applications. The ... at a rate of 4%, with world market ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS confirma su posición en un entorno difícil 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3
(Date:12/20/2014)... 2014 Developers of FCPX ... new plugin for Final Cut Pro X entitled TranSlice ... 5 allows users to create hand drawn text animations ... Austin, CEO of Pixel Film Studios. “TranSlice Volume 5 ... maintaining an easy to use interface.” , TranSlice Volume ...
(Date:12/20/2014)... 20, 2014 Today, Balfleet.com, one of ... Christmas Sale, offering 50%-70% off on its Mother ... , The mother of the bride dresses from Balfleet.com ... is 24/7 accessible and takes pride in providing high ... “We are offering great discounts on our mother of ...
(Date:12/19/2014)... Sub Zero Ice Cream is partnering up with the ... 28th from 2pm-6pm at the Expo Center on the northeast ... , Inquiries regarding time slots and signing up, email todd.subzeroicecream(at)gmail(dot)com. ... process, Sub Zero Ice Cream & Yogurt will be offering ... About Sub Zero Ice Cream & Yogurt , Sub ...
(Date:12/19/2014)... CA (PRWEB) December 19, 2014 SuperCloset ... 5x5 SuperClone Rooms. SuperCloset continues to offer indoor growers ... Pair one of the new SuperClone Rooms with the ... perpetual, and turnkey indoor hydroponic grow room setup. , ... the world, SuperCloset’s SuperPonic SuperCloner 50 . ...
(Date:12/19/2014)... 2014 The Medspa at Hendrick in ... from respected cosmetic brand Juvéderm. Voluma XC treats volume ... The Medspa at Hendrick is pleased to be able ... technology to its clients. , Voluma is the first ... to treat the mid-face and cheek area. This non-invasive ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Shark Tank’s Sub Zero Ice Cream Sponsors Blood Drive 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2
... either way because of salty sauces , , MONDAY, Oct. 20 ... that are staples of the Western diet account for about ... new report suggests. , Meanwhile, a diet rich in fruits ... risk of heart attack, according to the study, published in ...
... heart attacks , , MONDAY, Oct. 20 (HealthDay News) -- A ... reduce the risks of surgery. , The death rate for ... higher in the 30 days after an operation than for ... according to a report in the October issue of the ...
... risk of chronic diseases and,can help reduce health care ... Oct. 20 Small steps can lead to big,health ... campaign,launched today. As families stretch to make ends meet ... American Medical Association,s campaign,can help people live a healthy ...
... 20 Lincare Holdings,Inc. (Nasdaq: LNCR ), a ... to patients in the home, today announced,financial results for ... For the quarter ended September 30, 2008, revenues ... the third quarter of 2007. The,Company estimates that the ...
... 20 Insulet Corporation,(Nasdaq: PODD ), the leader ... today announced the appointment of Sally W.,Crawford to its ... the former chief operating officer of Healthsource Inc., a ... Partners, a venture,capital firm in life sciences, on Insulet,s ...
... play a major role, study suggests , , MONDAY, Oct. ... likely to die in U.S. emergency rooms after a ... uninsured ER patients are more likely to die compared ... October issue of the Archives of Surgery . ...
Cached Medicine News:Health News:Western Diet Boosts Global Heart Attack Risk 30% 2Health News:Questions Continue About Using Beta Blockers Before Surgery 2Health News:Questions Continue About Using Beta Blockers Before Surgery 3Health News:AMA Aims to Help Americans Get Healthier One Step at a Time 2Health News:Lincare Holdings Inc. Announces Third Quarter and First Nine Months 2008 Financial Results 2Health News:Lincare Holdings Inc. Announces Third Quarter and First Nine Months 2008 Financial Results 3Health News:Lincare Holdings Inc. Announces Third Quarter and First Nine Months 2008 Financial Results 4Health News:Lincare Holdings Inc. Announces Third Quarter and First Nine Months 2008 Financial Results 5Health News:Lincare Holdings Inc. Announces Third Quarter and First Nine Months 2008 Financial Results 6Health News:Sally W. Crawford Joins Insulet's Board of Directors 2Health News:Sally W. Crawford Joins Insulet's Board of Directors 3Health News:Sally W. Crawford Joins Insulet's Board of Directors 4Health News:Minorities More Likely to Die in ER 2Health News:Minorities More Likely to Die in ER 3
PremierEdge Stab Knives - 30....
PremierEdge™ Stab Knives - 15°....
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Medicine Products: